Sichuan Huiyu Pharmaceutical Co., Ltd.

The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in healthy participants under fasting condition. The main questions it aims to answer are:
* [Question 1] Is there significant difference in the pharmacokinetic profile between the ferric carboxymaltose injection 750 mg iron/15 mL provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and the ferric carboxymaltose injection licensed by American Regent, Inc. (trade name: Injectafer®, strength:750 mg iron/15 mL )?
* [Question 2] Is it safe for healthy participants to take ferric carboxymaltose injection (750 mg iron/15 mL [calculated by iron]) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. under fasting condition? Participants will be randomly divided into two groups by stratified blocked randomization, with equal number of healthy participants in each group, to receive test product or reference product according to the protocol below.
* Dosing on D1: Group T (Test product) Group R (Reference product)
* PK blood sample collection
* Safety evaluation

主要目的：以南京恩泰医药科技有限公司研制的注射用T001（规格：10mg）为试验药，氢化泼尼松注射液（规格：10mg）为对照药，考察试验药和对照药在中国健康受试者空腹状态下静脉滴注单次给药的药代动力学参数，评价两制剂的药代动力学相似性。 次要目的：评估南京恩泰医药科技有限公司研制的注射用T001 的安全性。

主要目的：比较空腹给药条件下，四川汇宇制药股份有限公司提供的异麦芽糖酐铁注射液（规格：1000 mg/10 mL）与Pharmacosmos A/S持证的异麦芽糖酐铁注射液（商品名：MonoFer®，规格：1 g/10 mL）在缺铁性贫血参与者中吸收程度和速度的差异，估算其药代动力学参数，用于计算和调整正式试验样本量，同时验证分析方法、试验流程、采血点和试验设计的合理性。 次要目的：评价空腹给药条件下，四川汇宇制药股份有限公司提供的异麦芽糖酐铁注射液（规格：1000 mg/10 mL）的安全性。